Investigation of clinical interaction between omeprazole and tacrolimus in CYP3A5 non-expressors, renal transplant recipients by Katsakiori, Paraskevi F et al.
© 2010 Katsakiori et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Therapeutics and Clinical Risk Management 2010:6 265–269
Therapeutics and Clinical Risk Management Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
265
ORiginAL ReseARCh
open access to scientific and medical research
Open Access Full Text Article
11501
investigation of clinical interaction between 
omeprazole and tacrolimus in CYP3A5  
non-expressors, renal transplant recipients
Paraskevi F Katsakiori1
eirini P Papapetrou2
Dimitrios s goumenos3
george C nikiforidis4
Christodoulos s Flordellis1
Departments of 1Pharmacology, 
3internal Medicine-nephrology, 
4Medical Physics, school of Medicine, 
University of Patras, Rion, greece; 
2Center for Cell engineering, 
Molecular Pharmacology and 
Chemistry Program, Memorial  
sloan-Kettering Cancer Center,  
new York, nY, UsA
Correspondence: Paraskevi F Katsakiori 
Department of Pharmacology, school of 
Medicine, University of Patras,  
Rion, greece
Tel +30 6937 438208
email vkatsak@med.upatras.gr
Background: As proton pump inhibitors share CYP3A4 enzyme with tacrolimus for their 
hepatic elimination, they potentially affect its pharmacokinetics, most prominently in patients 
with CYP2C19 or CYP3A5 gene mutations. Our aim was to investigate the impact of omeprazole 
on tacrolimus pharmacokinetics in CYP3A5 non-expressors, kidney transplant recipients.
Methods: Twelve patients (five males/seven females) were observed for 175 ± 92.05 days. 
Omeprazole (20 mg pos) was administrated for 75.83 ± 45.17 days. Immunosuppressant regi-
men consisted of tacrolimus (n = 12), methylprednisolone (n = 10), mycophenolate mofetil 
(n = 11), azathioprine (n = 1), and everolimus (n = 2). Patient’s body weight, coadministered 
drugs, and tacrolimus trough levels were monitored. Aspartate and alanine aminotransferase, 
γ-glutamyltransferase, and bilirubin were used for evaluating hepatic function. Tacrolimus 
kinetics were estimated with daily dose, concentration, dose adjusted concentration, and volume 
of distribution with and without coadministration of omeprazole. CYP3A5 genotyping was 
performed with PCR followed by restriction fragment length polymorphism analysis. Statistical 
analysis was performed with Prism 4 software (GraphPad Software, Inc).
Results: No statistically significant difference was observed in tacrolimus kinetics and hepatic 
function during coadministration of omeprazole.
Conclusion: Our results let us propose that there is no need for more frequent therapeutic 
drug monitoring of tacrolimus when coadministrated with omeprazole in CYP3A5 nonexpres-
sors, though prospective studies with more patients and longer observation period are needed 
to confirm these findings.
Keywords: CYP3A5, omeprazole, renal transplantation, tacrolimus
Introduction
Proton-pump inhibitors (PPIs) are commonly administrated to transplanted patients to 
prevent stress-related gastric bleeding or gastrointestinal ulceration. In humans, PPIs 
are metabolized by cytochrome P450 (CYP) enzymatic system, mainly by CYP2C19 
and CYP3A4.1–3 Systemic clearance of tacrolimus (TAC), the main immunosuppressant 
drug agent, is performed via CYP3A4 and CYP3A5.4–6 As PPIs and TAC share CYP3A4 
enzyme for their hepatic elimination, PPIs may potentially affect TAC pharmacokinet-
ics, most prominently in patients with CYP2C19 or CYP3A5 gene mutations.
The presence of clinically relevant pharmacokinetic drug interaction between omepra-
zole and TAC remains a matter of controversy.2,3,7–10 Omeprazole is metabolized into its 
major primary metabolites by CYP2C19 with a minor contribution of CYP3A4.2,3 In case 
of CYP2C19 gene mutation (poor metabolizers) or if high doses of omeprazole (40 mg) 
are given to extensive metabolizers, CYP3A4 becomes the main elimination enzyme for Therapeutics and Clinical Risk Management 2010:6
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Figure 1 RFLP for CYP3A5. Lane M, base pair marker (250-bp DnA ladder); lanes 
1–3, sspi-digested PCR products from three PCR products. CYP3A5*3/*3 genotype 
gives 168- and 125-bp bands (lane 3) and CYP3A5*1/*3 genotype gives 168-, 148-, 
125-, and 20-bp (lanes 1 and 2). The 20-bp band is not visible. CYP3A5*1/*1 genotype 
is not seen in this picture. Analysis on a 3.5% agarose/Tris-borate-eDTA gel.
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omeprazole.9 In vivo studies using human liver microsomes 
have shown that omeprazole inhibits CYP3A4-mediated 
metabolism of TAC competitively.7,8 Takahashi et al proposed 
rabeprazole as a safer treatment option than omeprazole in 
kidney transplant recipients receiving TAC.11   Lemahieu et al 
examined the impact of cimetidine and omeprazole on TAC 
exposure and on CYP3A4/PGP activity in vivo and concluded 
that switching treatment with cimetidine to omeprazole in renal 
transplant recipients is associated with a decrease of dose/
weight normalized trough levels of TAC.12 In contrast, Pascual 
et al estimated the potential interaction between omeprazole 
and TAC in renal transplant recipients and concluded to 
absence of important drug interaction.10
Defective CYP3A5 genotype may reveal potential 
CYP3A4-mediated drug interaction between TAC and 
omeprazole. CYP3A5 may account for more than 50% of 
whole hepatic CYP3A in individuals who express it. There-
fore, it is the main genetic factor responsible for the inter-
individual variation of kinetics of drugs that are metabolized 
by CYP3A family.13 Although CYP3A5 polymorphisms 
seem to have greater importance than those of CYP3A4, non-
expressors may sometimes not be distinct because many drugs 
are metabolized by both CYP3A5 and CYP3A4.14 The most 
important polymorphism in CYP3A5 gene is CYP3A5*1 
(A6986G) which is situated in intron 3.4–6 Individuals carry-
ing at least one CYP3A5*1 (g6986A) allele express CYP3A5 
whereas subjects homozygotes for CYP3A5*3 (g6986G) 
allele do not express CYP3A5 protein.13
The aim of the present study was to investigate the impact 
of omeprazole on TAC pharmacokinetics in CYP3A5 non-
expressors, kidney transplant recipients.
Subjects and methods
subjects
Twelve individuals (five males/seven females), who received 
a kidney transplant for end stage chronic renal insufficiency 
and attended the Outpatient Clinic of Nephrology in our 
institution, were selected to participate in the study. Informed 
consent was obtained from each participant.
Patients had received the kidney transplant 699.83 ± 969. 
13 days ago, the average observation time was 175 ± 92.05 
days and omeprazole treatment (20 mg pos) was admin-
istrated for 75.83 ± 45.17 days. The immunosuppressant 
regimen consisted of TAC (n = 12), methylprednisolone 
(n = 10), mycophenolate mofetil (n = 11), azathioprine 
(n = 1), and everolimus (n = 2). TAC was taken twice a day 
and its blood concentration was measured 12 hours post 
night dose at repeated time points. Patient’s body weight, 
coadministered drug agents, TAC trough levels, and blood 
chemistry were monitored during the study time. TAC dose 
adjusted concentration and volume of distribution (dose/
concentration ratio) were calculated.
Concomitant medication was allowed only if it had been 
started 1 month before the initiation of the study especially 
if the administrated drugs influenced the kinetics of tacroli-
mus or omeprazole. Coadministrated treatment included 
drug agents for coronary heart disease, diabetes mellitus, 
thyroid gland disorders, hypertension, hyperuricemia, 
hypertriglyceridemia/hyperlipidemia, osteoporosis, anemia 
(iron-deficiency etc), magnesium disorders, and antibiotic 
prophylaxis.
CYP3A5 genotype determination
Genomic DNA was extracted from the 200 µL ethylene-
diaminetetracetic acid-treated whole blood sample with the 
use of QIAamp DNA Blood kit (QIACEN GmbH). CYP3A5 
genotyping was performed with PCR followed by restric-
tion fragment length polymorphism analysis (RFLP). In 
accordance to van Schaik et al the forward primer used was 
5′-CATCAGTTAGTAGACAGATGA-3′ and the reverse one 
5′-GGTCCAAACAGGGAAGAAATA-3′.13 These primers 
amplified a 293-bp fragment of CYP3A5. PCR conditions 
were 1 min at 94°C, 40 cycles of 1 min at 94°C, 1 min at 
55°C, 1 min at 72°C, and a final extension of 7 min at 7°C. 
Digestion of PCR product was performed with the use of 
SspI endonuclease (New England BioLabs Inc.) and the 
digestion products were separated with 3.5% agarose/Tris-
borate EDTA gel electrophoresis and ethidium bromide 
staining (Figure 1). CYP3A5*1/*1 genotype gave 148-, 
125-, and 20-bp bands; CYP3A5*3/*3 genotype 168- and 
125-bp bands; and CYP3A5*1/*3 genotype 168-, 148-, 125-, 
and 20-bp.13Therapeutics and Clinical Risk Management 2010:6
Table 1 Characteristics of patient population
Characteristic
Age (years, mean (sD)) 35.08 (16.31)
gender (male/female) 5/7
Weight (kg, mean (sD)) 69.63 (8.46)
Transplantation number (first/second) 10/2
Cadaver transplant donor 12
Age at the onset of the chronic renal deficiency  
(years, mean (sD))
30.58 (15.53)
Table 2 Tacrolimus pharmacokinetics and hepatic function with 
and without coadministration of omeprazole
Parameter With  
(mean ± SD)
Without  
(mean ± SD)
P
Concentration  
(ng/mL)
9.80 ± 3.70 9.32 ± 3.86 0.3409
Daily dose  
(mg/kg/day)
0.10 ± 0.05 0.11 ± 0.07 0.2335
Concentration/dose  
((ng/mL)/(mg/kg))
135.05 ± 93.96 129.16 ± 92.39 0.7203
Volume of  
distribution (L/kg)
11.12 ± 7.48 13.06 ± 13.25 0.7182
Aspartate  
aminotransferase (U/L)
17 ± 9 18 ± 7 0.0718
Alanine  
aminotransferase (U/L)
24 ± 18 22 ± 15 0.9791
γ-glutamyltransferase (U/L) 27.81 ± 16.79 28 ± 24 0.3447
Bilirubin (mg/dL) 0.50 ± 0.24 0.51 ± 0.23 0.6327
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statistical analysis
TAC pharmacokinetics were estimated with the use of TAC 
daily dose, concentration, dose adjusted concentration, and 
volume of distribution (dose/concentration ratio), with and 
without coadministration of omeprazole. Aspartate amin-
otransferase, alanine aminotransferase, γ-glutamyltransferase, 
and bilirubin were used for the evaluation of hepatic 
function.
Statistical calculations and analyses were performed 
with the use of Prism 4 (GraphPad Software, Inc) statistical 
software package. Continuous data were tested with Kolm-
ogorov’s normality test to estimate whether originated from 
normal distribution or not. Student’s t-test was used for test-
ing the significance of difference of variables that passed the 
normality test. Mann-Whitney test was used for continuous 
variables that did not pass the normality test. All statistical 
tests performed were two-sided. The threshold of statistical 
significance was set at 5% (a = 0.05).
Results
The characteristics of the study population are presented 
in Table 1. The etiology of the primary kidney disease was 
unknown (n = 2), cystoureteral reflux (n = 2), polycystic 
kidney disease (n = 1), diabetic nephropathy (n = 1), Alport 
syndrome (n = 1), eclampsia (n = 1), antiphospholipidic syn-
drome/systemic lupus erythematosus (n = 1), nephrolithiasis 
(n = 1), nephronophthisis (n = 1), and IgΑ nephropathy 
(n = 1).
No statistically significant difference was observed 
in TAC pharmacokinetics during the coadministration of 
omeprazole (Table 2). No statistically significant difference 
was observed in aspartate aminotransferase, alanine amin-
otransferase, γ-glutamyltransferase, and bilirubin during the 
concomitant use of omeprazole (Table 2).
Discussion
Defective CYP3A5 genotype in renal transplanted patients 
could reveal the CYP3A4-mediated drug interaction between 
TAC and omeprazole. The contribution of CYP3A5 to the 
interaction between TAC and omeprazole remains unclear. 
Seventy-five percent of whites and 50% of African Americans 
do not express functional CYP3A5.14 In the Greek population, 
the CYP3A5*3 allele shows an allelic frequency of 94.35% 
whereas individuals homozygous for CYP3A5*3 show a 
frequency of 88.69%.15 In our study, the participants were 
CYP3A5 nonexpressors to ensure that TAC is metabolized 
through CYP3A4 and thereby, share this cytochrome with 
omeprazole.
To our knowledge, up to now clinical significance of 
pharmacokinetic drug interactions between PPIs and TAC 
has mainly been investigated in case reports and inadequately 
estimated in clinical trials. Namely, no clear clinically rel-
evant interaction between TAC and omeprazole has been 
reported and the results of the studies are controversial. 
Although omeprazole inhibits the in vitro metabolism of 
TAC by human liver microsomes, no clinical study is avail-
able on the relevance of such an interaction among transplant 
patients.7,8 Additionally, although interaction of omeprazole 
with TAC may involve inhibition of hepatic and intestinal 
CYP3A4, intestinal PGP, and pharmacokinetic characteristics 
of omeprazole, the only reported interactions between TAC 
and other PPI have been described in subjects with CYP2C19 
gene variants.16–18 More specifically, increased blood concen-
tration of omeprazole can cause CYP3A4 overload and result 
in interaction in this pathway in patients with CYP2C19 gene 
mutations as pharmacokinetic profiles of omeprazole and lan-
zoprazole depend on the CYP2C19 genotype status.11,17,19
Because PPIs and TAC share the CYP3A4 system for 
their hepatic elimination, PPIs may potentially inhibit TAC 
metabolism via CYP3A4 thereby increasing drug blood Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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concentrations, especially in patients with CYP2C19 gene 
mutations.19,20 In the Greek population, CYP2C19*2 allele 
show an allelic frequency of 13.07% whereas none of 283 
subjects studied was found to possess the CYP2C19*3 
allele.15 Caucasian subjects with *1/*1 and *1/*17 geno-
type need stronger acid-suppression therapy compared to 
CYP2C19*2/*2, especially during the first days of treatment 
or with on-demand therapy.21
Omeprazole is known to have the most pharmacokinetic 
interactions with TAC, compared to other PPIs. However, 
Pascual et al estimated the potential interaction between 
omeprazole and TAC in renal transplant recipients and con-
cluded to absence of important drug interaction between 
omeprazole and TAC in the general transplant population.10 
Although other PPIs have fewer documented drug interac-
tions than omeprazole, recently Takahashi et al showed 
important interactions between lansoprazole and TAC.22
In our study, no statistically significant difference was 
found in the pharmacokinetic parameters of TAC with coad-
ministration of omeprazole. Additionaly, we report no sta-
tistically significant difference in hepatic function. Hosohata 
et al reported that intestinal and graft liver CYP2C19 plays a 
relatively greater role in the metabolism of omeprazole than 
it does for lansoprazole, so that the effects of CYP3A5 on the 
metabolism of TAC might be masked by the interaction 
with omeprazole associated with the CYP2C19 genotype.23 
Studies in healthy volunteers suggest that a decrease of dose/
weight normalized trough levels of TAC may be explained 
by an increase of intestinal CYP3A4 activity.12
This was the first attempt to study TAC kinetics in 
Greek renal transplant patients. CYP3A5*3 is a common 
polymorphism among Greeks. Detection of CYP2C19 
polymorphisms was not performed as a previous study 
showed that they are rare in Greeks and we assumed that 
our patients were not CYP2C19 polymorphic.15 The absence 
of CYP3A5 expression was used to reveal the CYP3A4-
mediated drug interaction between TAC and omeprazole. 
Although patient’s epigenetic characteristics (including age, 
dietary, and other habits) are known to affect TAC kinetics, 
these parameters were not studied here because of the small 
number of patients.
Since genetic information is not usually clinically avail-
able for each patient, careful monitoring of TAC trough levels 
is, still, needed to optimize the dosage regimen in patients 
receiving TAC. Our results let us propose that there is no need 
for more frequent therapeutic drug monitoring of TAC when 
coadministrated with omeprazole in CYP3A5 nonexpressors. 
However, due to restricted number of patients, prospective 
studies with greater number of patients and   longer obser-
vation time are deemed necessary to further evaluate the 
clinical impact of interaction, if it exists, between TAC and 
omeprazole.
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